Keywords: Pfizer, Medivation, Alzheimer's disease, Dimebon, CONCERT trial, Huntington Disease

Pfizer, Medivation finally pull plug on Dimebon

Article | 18 January 2012

Following previous disappointing clinical trials results for their potential Alzheimer’s drug candidate, USA-based Medivation (Nasdaq: MDVN) and global ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Pfizer

Medivation

Go to company listing

Related Drugs

Dimebon

Go to drug listing